<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03337698</url>
  </required_header>
  <id_info>
    <org_study_id>BO39610</org_study_id>
    <secondary_id>2017-001267-21</secondary_id>
    <nct_id>NCT03337698</nct_id>
  </id_info>
  <brief_title>A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)</brief_title>
  <acronym>Morpheus Lung</acronym>
  <official_title>A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based
      treatment combinations in patients with metastatic non-small cell lung cancer (NSCLC).

      Two cohorts will be enrolled in parallel in this study: the first-line (1L) cohort will
      consist of patients who have not received any systemic therapy for their disease and the
      second-line (2L) cohort will consist of patients who progressed during or after receiving a
      platinum-containing regimen and a PD-L1/PD-1 checkpoint inhibitor treatment. In each cohort,
      eligible patients will be assigned to one of several treatment arms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">April 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Objective Response</measure>
    <time_frame>Every 6 weeks (starting on Day 1, Cycle 1) for the first 48 weeks and then every 6 or 12 weeks thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival After Randomization</measure>
    <time_frame>Randomization to death from any cause (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Alive at Month 6 and at Month 12</measure>
    <time_frame>Month 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>First occurrence of a documented objective response to disease progression or death (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Baseline through the end of the study (approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Anticipated">305</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the Atezolizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.
Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.
Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or disease progression.
Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + CPI-444</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + CPI-444 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Ipatasertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + Ipatasertib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Idasanutlin + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Idasanutlin + Docetaxel arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Atezolizumab + Bevacizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Participants who have received treatment with Atezolizumab + Docetaxel in Stage 1 will not receive this treatment in Stage 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + Linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + Linagliptin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.</description>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab</arm_group_label>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + CPI-444</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Docetaxel</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Ipatasertib</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin</arm_group_label>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin</arm_group_label>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + Docetaxel</arm_group_label>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + Linagliptin</arm_group_label>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Cobimetinib is administered orally on Days 1-21 of a 28 day cycle.</description>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Cobimetinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6958688</intervention_name>
    <description>Cycle 1:
RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage.
Subsequent cycles:
RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle</description>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel is administered by IV on Day 1 of each 21 day cycle. When combined with idasanutlin, docetaxel is administered by IV on Days 1 and 15 of each 28 day cycle.</description>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Docetaxel</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Docetaxel</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Idasanutlin + Docetaxel</arm_group_label>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-444</intervention_name>
    <description>CPI-444 is administered orally twice daily on Days 1- 21, of a 21 day cycle.</description>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + CPI-444</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed is administered by IV on Day 1 of a 21 day cycle.</description>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.</description>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin</arm_group_label>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle</description>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Linagliptin is administered orally once daily on Days 1 to 21 out of a 21 day cycle</description>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + Linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.</description>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipatasertib</intervention_name>
    <description>Ipatasertib will be administered orally once a day on Days 1-21 of each 28-day cycle.</description>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Ipatasertib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idasanutlin</intervention_name>
    <description>Idasanutlin will be administered orally once a day on Days 1-5 of each 28 day cycle.</description>
    <arm_group_label>Stage 1: Cohort 2: Idasanutlin + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab is administered by IV on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance Status of 0 or 1

          -  Life expectancy greater than or equal to 3 months

          -  Histologically or cytologically confirmed metastatic, non-squamous or squamous
             Non-Small Cell Lung Cancer (NSCLC)

          -  Measurable disease (at least one target lesion)

          -  Adequate hematologic and end-organ function

          -  Tumor accessible for biopsy

          -  Availability of peripheral blood for next-generation sequencing (NGS) circulating
             tumor deoxyribonucleic acid (ctDNA) testing.

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive measures and agreement to refrain from
             donating eggs as outlined for each specific treatment arm

          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures, and agreement to refrain from donating sperm, as outlined for
             each specific treatment arm

        Inclusion Criteria for Cohort 1

          -  No prior systemic therapy for metastatic NSCLC

          -  High tumor PD-L1 expression, defined as Tumor Proportion Score (TPS) &gt;= 50%

        Inclusion Criteria for Cohort 2

        - Disease progression during or following treatment for metastatic or locally advanced,
        inoperable NSCLC

        Exclusion Criteria

          -  Prior allogeneic stem cell or solid organ transplantation

          -  Current treatment with anti-viral therapy for hepatitis B virus (HBV)

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures (once monthly or more frequently)

          -  Symptomatic, untreated, or actively progressing central nervous system (CNS)
             metastases

          -  History of leptomeningeal disease

          -  Active or history of autoimmune disease or immune deficiency

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of
             active pneumonitis on screening chest computed tomography scan

          -  History of malignancy other than NSCLC within 2 years prior to screening

          -  Active tuberculosis

          -  Severe infection within 4 weeks prior to initiation of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BO39610 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center; Research Pharmacy, Irving Pavillion, Ip 7-749</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter Mac Callum Cancer Center</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse-Oncopole; PHARMACIE</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center; Oncology</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4922297</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center; Oncology Dept</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52620-00</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC)</name>
      <address>
        <city>Songpa-gu</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31620</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundación Jimenez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics Madrid - CIOCC - Universitario Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barts Cancer Institute</name>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital; Institute of Cancer Research</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 7, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

